Emergent Biosolutions
EBS
190 hedge funds and large institutions have $361M invested in Emergent Biosolutions in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 70 increasing their positions, 53 reducing their positions, and 26 closing their positions.
244% more call options, than puts
Call options by funds: $3.9M | Put options by funds: $1.13M
42% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 26
32% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 53
4% more funds holding
Funds holding: 183 → 190 (+7)
1.45% more ownership
Funds ownership: 82.65% → 84.11% (+1.5%)
33% less capital invested
Capital invested by funds: $537M → $361M (-$176M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$6.62M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.23M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$4.31M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OHA
Oak Hill Advisors
New York
|
-$25.9M |
| 2 |
JG
Jain Global
New York
|
-$7.7M |
| 3 |
Morgan Stanley
New York
|
-$4.28M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.41M |
| 5 |
Jane Street
New York
|
-$2.88M |
EBS Hedge Fund Activity: Q1 2026 in Review
190 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2026, worth a combined $361M — down 33% from $537M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EBS positions and 26 closed out — a net gain of 11 holders — while 70 added to existing stakes and 53 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $6.62M. The largest seller was Oak Hill Advisors, cutting an estimated $25.9M.
- 190 institutional investors held Emergent Biosolutions (EBS) as of Q1 2026, up from 183 in Q4 2025.
- Funds reported $361M of Emergent Biosolutions stock for Q1 2026, down 33% quarter-over-quarter.
- 37 funds opened new Emergent Biosolutions positions in Q1 2026 and 26 closed out, a net change of +11 holders.
- The largest Emergent Biosolutions buyer in Q1 2026 was Prosight Management, an estimated $6.62M added.
- The largest Emergent Biosolutions seller in Q1 2026 was Oak Hill Advisors, an estimated $25.9M sold.
Based on aggregated 13F filings for Q1 2026.